The Aftermath of the Health Checkup 4: The Diagnosis

I was guided to the front of the examination room.It was my turn next.However, the nurse who came out of the examination room said, "Please wait just a little longer."An elderly man went into the ...
BIOENGINEER

Why EGFR Drugs Fail in Glioblastoma: A STAT3 Escape Route Takes Center Stage

A new review argues that glioblastoma evades EGFR-targeted therapies through compensatory STAT3 activation, positioning the ...
oncodaily

Chromosomal Abnormalities in Blood Cancers: How Cytogenetics Predicts Drug Sensitivity and Resistance

Gain of chromosome 1q21 can increase MCL1 expression, which may let leukemic cells survive BCL2 inhibition. Gain of 2p, ...

Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference

Updated preclinical data and clinical trial-in-progress poster from the Harmony-HHT Phase 1/2 trial support the ongoing development of ATV-1601, ...
medfind

原发性血小板增多症耐药怎么办？罗培干扰素α-2b获FDA批准打破近30年治疗僵局

原发性血小板增多症（ET）患者面临羟基脲耐药或不耐受时该如何破局？美国FDA正式批准长效干扰素罗培干扰素α-2b上市，成为近30年来该领域首个突破性新药。III期临床数据显示其不仅能持久稳定血小板计数，更能从源头清除异常克隆并降低JAK2突变负荷。了 ...
medfind

原发性血小板增多症近30年首迎新药：罗培干扰素α-2b获批带来深度缓解新希望

原发性血小板增多症（ET）患者面临羟基脲耐药与血栓风险怎么办？美国FDA正式批准长效罗培干扰素α-2b用于成人ET治疗。基于III期SURPASS-ET研究，该药在持久血液学应答、降低血栓事件及清除突变克隆上显著优于传统药物阿那格雷，为突破疾病进展瓶 ...

Société Cogent Biosciences, Inc.

Cogent Biosciences, Inc.: Présentation de la société Cogent Biosciences, Inc., actionnaires, dirigeants, description métier, rating financiers, communiqués officiels, coordonnées et codes boursiers | ...